Pfizer Inc. (PFE.DE)
| Previous close | 24.05 |
| Open | 24.09 |
| Bid | 24.08 x 0 |
| Ask | 24.11 x 0 |
| Day's range | 24.08 - 24.25 |
| 52-week range | 23.53 - 37.50 |
| Volume | |
| Avg. volume | 88,086 |
| Market cap | 136.467B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 68.86 |
| EPS (TTM) | 0.35 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 1.57 (6.53%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- Reuters
UPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug
The U.S. Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating cervical cancer patients whose disease had progressed on or after chemotherapy, the agency said on Monday. The treatment, Tivdak - an antibody-drug conjugate co-developed by Genmab A/S and Seagen - received the FDA's accelerated approval for the same indication in 2021. It was added to Pfizer's oncology portfolio last year through a $43 billion deal to acquire Seagen, along with other targeted cancer therapies.
